Arcus Biosciences Inc.
RCUS | NYSE
$26.55
+$0.60 (+2.31%)
Sep 22, 2026, 1:47 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -7.24 | -4.74 | -4.60 | -5.57 | 53.25 | -12.19 |
PEG Ratio | -1.52 | 0.19 | -0.39 | 0.01 | -0.39 | -0.53 |
PS Ratio | 10.36 | 5.20 | 12.08 | 13.29 | 7.33 | 18.23 |
PB Ratio | 4.06 | 2.77 | 3.06 | 2.27 | 3.34 | 2.83 |
P/FCF Ratio | -5.29 | -7.62 | -4.28 | 3.45 | -9.94 | 13.16 |
P/OCF Ratio | -5.31 | -7.89 | -4.62 | 3.40 | -10.96 | 12.79 |
OCF/S Ratio | -195.14 | -65.89 | -261.54 | 391.07 | -66.89 | 142.53 |
Debt / Equity Ratio | 0.18 | 0.12 | 0.02 | 0.18 | 0.14 | 0.04 |
Quick Ratio | 4.36 | 4.50 | 4.52 | 5.52 | 7.60 | 6.05 |
Current Ratio | 4.36 | 4.50 | 4.52 | 5.52 | 7.60 | 6.05 |
Asset Turnover | 0.22 | 0.22 | 0.11 | 0.08 | 0.24 | 0.10 |
Interest Coverage | -48.25 | -82.50 | -170 | -140 | n/a | n/a |
Return on Equity | -55.94% | -58.35% | -66.45% | -40.64% | 6.30% | -24.49% |
Return on Assets | -30.99% | -24.61% | -28.04% | -19.85% | 3.33% | -15.93% |
Return on Invested Capital | -41.91% | -35.26% | -36.88% | -24.24% | 3.64% | -18.98% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 95.95% | 100% | 100% | 100% | 100% | 100% |
Net Profit Margin | -142.91% | -109.69% | -262.39% | -238.39% | 13.84% | -157.69% |
Pretax Profit Margin | -142.91% | -109.69% | -257.26% | -237.50% | 14.36% | -157.69% |
Operating Profit Margin | -156.28% | -127.91% | -290.60% | -250% | 14.10% | -158.97% |
FCF Margin | -195.95% | -68.22% | -282.05% | 385.71% | -73.69% | 138.61% |
EBITDA Margin | -135.63% | -104.26% | -248.72% | -230.36% | 15.40% | -153.85% |
Add to Watchlist
Select watchlists to add or remove RCUS